Back to search

National and Kapodistrian University of Athens

Τομογραφία εκπομπής ποζιτρονίων (pet/ct scan) στο λέμφωμα hodgkin: συσχέτιση με τη θεραπευτική στρατηγική και την ακτινοθεραπεία

Abstract

dc:description

Introduction:The effect of baseline positron emission tomography combined with computed tomography (PET/CT) on first-line treatment choice in Hodgkin lymphoma (HL) has not been systematically studied outside clinical trials.Aim: The aim of this study was the investigation of the potential impact of baseline PET/CT on staging, modification of therapeutic strategy and involved-field radiotherapy fields (IF-RT) in every day practice and the assessment of the prognostic significance of baseline PET/CT parameters.Patients and Methods: Between 12/12/2006 and 25/7/2014, 162 consecutive patients with HL, were retrospectively studied. They were selected solely based on both baseline CT and PET/CT availability.Results: Twenty-six (16%) patients were upstaged and 9 (6%) downstaged. The number of involved sites (NIS) by PET-staging (PET-S) was significantly higher compared to clinical staging (CS) (p<0.0001). Treatment strategy (adjusted for early or advanced stage) could have been changed in 23 patients (14%) based on PET-S. However, in only 10 (6% of total) the treating physician decided to modify treatment, and this modification did not affect the outcome. In 66 patients PET-S could lead to modifications of IF-RT field, but such modifications were actually adopted in 36 (59%). The resulting extension of RT field did not affect outcome. Both PET-S and CS were highly significant in predicting freedom from progression (FFP) (p<0.001). Moreover, PET-S revealed three potent prognostic parameters: the NIS by PET-S, SUVmax and the product of (SUVmax)x(dmax) (dmax=maximal largest lesion diameter), as a surrogate of total lesion glycolysis (TLG). Patients with ≤ 2, 3-8, and >8 sites had 5y-FFP of 100%, 80% and 69% respectively (p=0.004). Patients with SUVmax≤ 9, 9-18 and >18 had 5-year FFP of 93%, 81% and 58% respectively (p=0.01), while (SUVmax)x(dmax) identified three groups of patients (≤ 35, 35.1-100 and >100) with significantly different prognosis (5-year FFP: 94%, 81% and 70% respectively, p=0.04). Conclusion: PET-S may alter clinical stage in 20% of HL patients, though with limited impact on treatment modification and outcome, and contributes to the identification of additional potent prognostic parameters.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mosa, Eftychia
  • Μόσα, Ευτυχία

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/42308

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mosa, Eftychia; Μόσα, Ευτυχία. Τομογραφία εκπομπής ποζιτρονίων (pet/ct scan) στο λέμφωμα hodgkin: συσχέτιση με τη θεραπευτική στρατηγική και την ακτινοθεραπεία. National and Kapodistrian University of Athens, 2017. http://hdl.handle.net/10442/hedi/42308